title: [Blood component replacement in bone marrow aplasia in patients after aggressive chemotherapy for malignant hematologic diseases].
abstract: Aggressive chemotherapy of malignant haematological diseases causes long-term aplasia of bone marrow and it is necessary to supplement blood elements repeatedly. When procuring blood derivates frequently dramatic situations develop. In an attempt to prevent alloimmunization of the patient by careful selection of the donor the time interval between indication and administration of the transfusion is prolonged. The objective of the present work was to attempt an estimate, as regards time and amount, for transfusion of blood derivates. The authors analyzed 100 cycles of aggressive chemotherapy with regard to changes of the haemogram. The group was divided arbitrarily with regard to the initial value of different components of the haemogram and for these portions of the group a time schedule of check-up examinations of the haemogram and of the assumed time of indication of transfusion of blood derivates was elaborated. In patients with an initial values of red blood cells above 3.5 x 10(12)/l the first transfusion is usually needed on the 8th day after the beginning of chemotherapy, in patients with a values lower than 3.0 x 10(12)/l after the initial supplementation a further drop may be expected already on the 4th day. Indication of replacement of thrombocytes can be expected in patients with an initial thrombocyte value above 120 x 10(9)/l cca on the 8th day, in patients with an initial thrombocyte value of 30 x 10(9)/l after initial replacement indication of another transfusion can be anticipated already on the 4th day after the beginning of chemotherapy.
authors.affiliation: II. interní klinika FNsP Brno Bohunice.
authors.forename: H
authors.initials: H
authors.lastname: Kubesová
authors.forename: E
authors.initials: E
authors.lastname: Krahulcová
authors.forename: I
authors.initials: I
authors.lastname: Kiss
authors.forename: J
authors.initials: J
authors.lastname: Vorlícek
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001772:Blood Cell Count / Q000187:drug effects; D016913:Blood Component Transfusion; D001853:Bone Marrow / Q000187:drug effects*; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male
chemical_list: D000970:Antineoplastic Agents
vernacular_title: Substituce krevními deriváty v období drenové aplázie u nemocných po agresivní chemoterapii zhoubných hematologických onemocnĕní.